尽管如此，礼来公司仍认为使用Zepbound进行美容减肥是不合适的。Eli Lilly and Co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
According to the Futu Securities APP, Eli Lilly and Co (LLY.US) is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight. The company's CEO, Dave Ricks, revealed that the company plans to test Zepbound as a health maintenance therapy for a target population with a Body Mass Index (BMI) below the overweight level. Currently, Zepbound and another weight loss candidate drug orforglipron from the company mainly target patients with a BMI of 30 and above, as well as patients with a BMI of 27 and above and other weight-related health problems.
Ricks stated that the company aims to lower the BMI threshold to 25 or lower to investigate the drug as a potential means of preventing diabetes, stroke, or vascular dementia. This strategy is particularly meaningful for certain populations with lower BMIs but higher risk of diabetes, such as Pacific Islanders.
However, Eli Lilly and Co still considers using Zepbound for cosmetic weight loss to be inappropriate.
It is understood that Zepbound, also known as tirzepatide, is a GLP-1 class drug, with its main competitor in the market being Novo Nordisk a/s' semaglutide, which is sold under the brands Ozempic and Wegovy.
GLP-1 class drugs are attracting attention due to their potential in weight loss and blood sugar control. In addition, several companies are actively developing weight loss drugs, including Amgen (AMGN.US), Pfizer (PFE.US), AstraZeneca (AZN.US), Roche (RHHBY.US), Bristol-Myers Squibb, Viking Therapeutics (VKTX.US), Altimmune (ALT.US), Zealand Pharma, and Sorrento Therapeutics (GPCR.US), all of which are seeking to develop new solutions for treating obesity and related diseases.
